Qureshi H, Ahsan T, Memon M.
Efficacy of CHO Cell derived Hepatitis B Vaccine in Children and Adults.
J Pak Med Assoc Jan ;52(3):128-9.

The present study was done to see whether low dose hepatitis B vaccination using CHO derived vaccine is able to produce sufficient immunity in Pakistani subjects. Fifty families residing in a communal compound volunteered for the study. All selected subjects were given 10 micrograms of Heprovac B Vaccine (recombinant CHO cell hepatitis B vaccine manufactured by Institute of Virology of Chinese Academy of Preventive Medicine) intramuscularly in the deltoid region at 0, 1 and 6 months. One hundred fifty eight (89 males and 69 females) volunteers with a mean (± SD) age of 25 t 16 years received 10 mcg dose of Heprovac-B vaccine (Hepatitis B vaccine) intramuscularly in the deltoid region at 0, 1 and 6 months. Of the total there were 54 children and 104 adults. Children were further divided into those aged 2 years to less than 5 years (15 children) and those aged 5-14 years (39 children). Antibody titers were checked after one month of every dose. Of all 158 subjects vaccinated, antibodies were produced successfully in 96.2% subjects, while 3.8% did not produce antibodies after the third dose. Of all the cases vaccinated > 10 IU antibodies were produced in 27.2% cases after the first dose, 72.8% after the second dose and 94.9% after the third dose with 5.1% non responders (1.3% producing less than 10 IU and 3.8% not producing antibodies) after the third dose. The geometric mean of antibodies was 26 IU after the first dose, 146 IU after the second and 353 IU after the third dose.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com